secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2022-03-07T23:59:59+00:00
Accession:  0001193125-22-068011
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Reneo appoints Michael P. Cruse as COO and Jennifer P. Lam as principal financial officer
--------------------------------------------------------------------------------

- Michael P. Cruse appointed COO effective March 2, 2022; base salary increased to $400K (from $350K) and bonus target to 40%.
- Cruse granted option for 25,000 shares vesting in 48 equal monthly installments; severance extended to 12 months post-change-of-control.
- Jennifer P. Lam named principal financial and accounting officer effective March 31, 2022; base salary raised to $320K (from $309K).
- Lam granted option for 10,000 shares vesting over 48 months; she previously served as VP of Finance & Administration since August 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/0001193125-22-068011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/d326180d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-068011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer